$0.72
0.00%
Nasdaq, Wed, Apr 02 2025
ISIN
US23254X2018
Symbol
CYTH
Sector
Industry

Cyclo Therapeutics Inc - Ordinary Shares - Class A Stock price

$0.72
-0.03 4.05% 1M
-0.01 1.42% 6M
+0.13 22.14% YTD
-0.74 50.64% 1Y
-2.49 77.55% 3Y
-18.78 96.30% 5Y
-54.27 98.69% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.00 0.00%
ISIN
US23254X2018
Symbol
CYTH
Sector
Industry

Key metrics

Market capitalization $20.62m
Enterprise Value $31.90m
P/E (TTM) P/E ratio negative
EV/Sales (TTM) EV/Sales 36.67
P/S ratio (TTM) P/S ratio 23.70
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -8.52%
Revenue (TTM) Revenue $870.00k
EBIT (operating result TTM) EBIT $-24.68m
Cash position $930.00k
EPS (TTM) EPS $-0.90
P/S forward 29.46
EV/Sales forward 45.57
Short interest 1.51%
Show more

Is Cyclo Therapeutics Inc - Ordinary Shares - Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Cyclo Therapeutics Inc - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Cyclo Therapeutics Inc - Ordinary Shares - Class A:

1x Hold
100%

Analyst Opinions

1 Analyst has issued a forecast Cyclo Therapeutics Inc - Ordinary Shares - Class A:

Hold
100%

Financial data from Cyclo Therapeutics Inc - Ordinary Shares - Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
0.87 0.87
8% 8%
100%
- Direct Costs 3.51 3.51
2% 2%
403%
-2.64 -2.64
0% 0%
-303%
- Selling and Administrative Expenses 6.06 6.06
70% 70%
697%
- Research and Development Expense 16 16
21% 21%
1,836%
-25 -25
27% 27%
-2,836%
- Depreciation and Amortization 0.01 0.01
50% 50%
1%
EBIT (Operating Income) EBIT -25 -25
27% 27%
-2,836%
Net Profit -25 -25
28% 28%
-2,851%

In millions USD.

Don't miss a Thing! We will send you all news about Cyclo Therapeutics Inc - Ordinary Shares - Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cyclo Therapeutics Inc - Ordinary Shares - Class A Stock News

Neutral
Business Wire
about one month ago
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Cyclo Therapeutics, Inc. (the “Company”) (NasdaqCM: CYTH) and Rafael Holdings, Inc. (NYSE: RFL). KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger ...
Neutral
Business Wire
about 2 months ago
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with rare and challenging diseases, today announced the presentation of data from its ongoing Pivotal Phase 3 global study (Trans...
Neutral
PRNewsWire
3 months ago
NEW YORK , Dec. 20, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Liberty TripAdvisor Holdings, Inc. (OTCMKTS: LTRPA, LTRPB)'s  sale to Tripadvisor, Inc. If you are a Liberty TripAdvisor shareholder, click here to...
More Cyclo Therapeutics Inc - Ordinary Shares - Class A News

Company Profile

Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. Its product candidates include Trappsol Cyclo, which treats Neimann-Pick Type C disease. The firm focuses on the development and commercialization of innovative cyclodextrin-based products for the treatment of people with serious and life threatening rare diseases and medical conditions. The company was founded by Charles E. Rick Strattan on August 9, 1990 and is headquartered in Gainesville, FL.

Head office United States
CEO Scott Fine
Founded 1990
Website www.cyclotherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today